Adenoviral Vaccines

Adenovirus-based vaccines have been shown to induce the highest B- and CD8+ T-cell responses against a variety of immunogens derived from a number of infectious agents (e.g., viruses, parasites, or bacterial pathogens) and tumor cells, including tumor-associated antigens (TAAs) in experimental animals and in human clinical trials. Ad-vectors can be propagated to high yields in well-defined production systems that are readily amenable to pharmaceutical scale production of clinical grade compositions.

Takis has generated Ad-vectors based cancer vaccines able to break immune tolerance against TAAs.